New results suggest that the reference regimen should be neoadjuvant therapy with modified FOLFIRINOX (oxaliplatin 85 mg/m 2, irinotecan 180 mg/m 2, leucovorin 400 mg/m 2, and infusional 5 ...

Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. Shares of ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer ...

Davendra Sohal of UC Health said Solomon was a good candidate for the trial after scans revealed his pancreatic cancer, which had spread to his liver, was not responding to standard therapy.

Novocure (NVCR) achieves milestone in pancreatic cancer treatment with positive trial results for TTFields therapy, leading to a 25% surge in stock price.

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer. ScienceDaily. Retrieved July 12, 2025 from www.sciencedaily.com / releases / 2025 / 03 / 250314170603.htm.